Spleen and bone marrow megakaryocytes as targets for inhaled vanadium.
An increased incidence in ischemic and thromboembolic events in the population of cities with rising air suspended particle pollution has suggested the interaction of some of the components of these particles in the coagulation system. A previous report from our laboratory identified thrombocytosis as a consequence of the subacute and chronic inhalation of vanadium. With this preceding information we decided to evaluate the effects of this element in the spleen and bone marrow in a mouse experimental model. CD-1 male mice inhaled V2O5 0.02 M for one hour twice a week for twelve weeks. The spleen and bone marrow were processed for light microscopy. The increase in quantity and size of megakaryocytes (MKs) in the exposed group in both organs was striking. Also, modifications in the cytoplasm, granule content and nuclear ultrastructure were evident. Our results indicate the influence of vanadium on megakaryopoyesis, an effect which could be the onset of the thrombocytosis previously reported by our group. The modifications in MKs described here suggest that inhaled vanadium could induce megakaryocytic proliferation, which may result in increased production of platelets and increased risk for thromboembolic events.
Fortoul
Teresa I
TI
Cellular and Tissular Biology Department, School of Medicine, National University of Mexico (UNAM), México City, México. fortoul@servidor.unam.mx
Piñón-Zarate
Gabriela
G
Diaz-Bech
Maria Eugenia
ME
González-Villalva
Adriana
A
Mussali-Galante
Patricia
P
Rodriguez-Lara
Vianey
V
Colin-Barenque
Laura
L
Martinez-Pedraza
Michelle
M
Montaño
Luis F
LF
D000818:Animals; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D048429:Cell Size / Q000187:drug effects; D019570:Inhalation Exposure; D008297:Male; D008533:Megakaryocytes / Q000187:drug effects* / Q000473:pathology; D051379:Mice; D023421:Models, Animal; D052638:Particulate Matter / Q000008:administration & dosage / Q000633:toxicity*; D013154:Spleen / Q000187:drug effects* / Q000473:pathology; D013923:Thromboembolism / Q000097:blood / Q000139:chemically induced; D034061:Thrombopoiesis / Q000187:drug effects*; D013997:Time Factors; D017968:Vanadium Compounds / Q000008:administration & dosage / Q000633:toxicity*
D052638:Particulate Matter; D017968:Vanadium Compounds; C066075:vanadium pentoxide